Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( MEGMI study)
Primary result · HbA1cResult — go to the resultChange difference −0.21 % 95% CI −0.41% to −0.01%Authors' conclusion
Imeglimin in combination with a dipeptidyl peptidase-4 inhibitor and low-dose metformin improved HbA1c compared with metformin dose escalation.
Study context
- Population
- Subjects with T2D treated with a DPP-4i plus low-dose metformin (500–1000 mg/day)65 in full analysis set
- Participants
- 73 subjects
- Comparison
- Adding imeglimin vs metformin dose escalation in T2D on DPP-4i plus low-dose metformin
- Imegliminn = 33
- Metformin escalationn = 32reference
- Primary endpoint
- Mean change in HbA1c
- Follow-up
- 24 weeks
Methodological detailsmulticentre, open-label, prospective, parallel-group
- Multicentre
- Open-label
- Prospective
- Parallel-group
Primary result
HbA1c
Change difference
−0.21 %
95% CI −0.41% to −0.01%
P = 0.038
By group
Imegliminvs Metformin escalation
change difference −0.21 % (95% CI −0.41% to −0.01%); P = 0.038
As reported in the abstract
Secondary outcomes
Body weight and liver enzymes (intra-group pre/post)
- Imeglimin significantly reduced body weight and improved liver enzyme elevation
HbA1c improvement vs fatty liver indicators
- Significant correlation between HbA1c improvement and indicators of fatty liver disease in the imeglimin group
Safety
- Discontinuation due to serious gastrointestinal adverse events — Imeglimin
- 7 events
Original publication
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( MEGMI study). Diabetes Obes Metab. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →